Neuropathic Pain - Pipeline Review, H2 2019
Neuropathic Pain - Pipeline Review, H2 2019
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain - Pipeline Review, H2 2019, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.
Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain (Neuralgia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 21, 46, 45, 1, 4, 157, 30 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 34 and 2 molecules, respectively.
Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain - Pipeline Review, H2 2019, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.
Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain (Neuralgia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 21, 46, 45, 1, 4, 157, 30 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 34 and 2 molecules, respectively.
Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Neuropathic Pain (Neuralgia) - Overview
Neuropathic Pain (Neuralgia) - Therapeutics Development
Neuropathic Pain (Neuralgia) - Therapeutics Assessment
Neuropathic Pain (Neuralgia) - Companies Involved in Therapeutics Development
Neuropathic Pain (Neuralgia) - Drug Profiles
Neuropathic Pain (Neuralgia) - Dormant Projects
Neuropathic Pain (Neuralgia) - Discontinued Products
Neuropathic Pain (Neuralgia) - Product Development Milestones
Appendix
Neuropathic Pain (Neuralgia) - Overview
Neuropathic Pain (Neuralgia) - Therapeutics Development
Neuropathic Pain (Neuralgia) - Therapeutics Assessment
Neuropathic Pain (Neuralgia) - Companies Involved in Therapeutics Development
Neuropathic Pain (Neuralgia) - Drug Profiles
Neuropathic Pain (Neuralgia) - Dormant Projects
Neuropathic Pain (Neuralgia) - Discontinued Products
Neuropathic Pain (Neuralgia) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Neuropathic Pain (Neuralgia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by 1st Bio Therapeutics Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Abalone Bio Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Achelios Therapeutics Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Acorda Therapeutics Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Adynxx Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AfaSci Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Affectis Pharmaceuticals AG, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Akelos Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Algiax Pharmaceuticals GmbH, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Algomedix Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Alion Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Allergan Plc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Allodynic Therapeutics LLC, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AlphaNavi Pharma Co Ltd, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Amgen Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AnaBios Corp, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Anavex Life Sciences Corp, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Andros Pharmaceuticals Co Ltd, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Angelini Group, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AngioChem Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Anida Pharma Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AnyGen Co Ltd, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AOBiome LLC, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by APT Therapeutics Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Aptarion biotech AG, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Aptinyx Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Aquilus Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Araim Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Arena Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Artelo Biosciences Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Asahi Kasei Pharma Corp, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Asarina Pharma AB, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Astellas Pharma Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Astraea Therapeutics LLC, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AstraZeneca Plc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Astrocyte Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AusCann Group Holdings Ltd, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Avanir Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Avilex Pharma ApS, H2 2019
Number of Products under Development for Neuropathic Pain (Neuralgia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by 1st Bio Therapeutics Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Abalone Bio Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Achelios Therapeutics Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Acorda Therapeutics Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Adynxx Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AfaSci Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Affectis Pharmaceuticals AG, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Akelos Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Algiax Pharmaceuticals GmbH, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Algomedix Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Alion Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Allergan Plc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Allodynic Therapeutics LLC, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AlphaNavi Pharma Co Ltd, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Amgen Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AnaBios Corp, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Anavex Life Sciences Corp, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Andros Pharmaceuticals Co Ltd, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Angelini Group, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AngioChem Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Anida Pharma Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AnyGen Co Ltd, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AOBiome LLC, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by APT Therapeutics Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Aptarion biotech AG, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Aptinyx Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Aquilus Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Araim Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Arena Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Artelo Biosciences Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Asahi Kasei Pharma Corp, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Asarina Pharma AB, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Astellas Pharma Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Astraea Therapeutics LLC, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AstraZeneca Plc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Astrocyte Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AusCann Group Holdings Ltd, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Avanir Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Avilex Pharma ApS, H2 2019
LIST OF FIGURES
Number of Products under Development for Neuropathic Pain (Neuralgia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
1st Bio Therapeutics Inc
Abalone Bio Inc
Achelios Therapeutics Inc
Acorda Therapeutics Inc
Adynxx Inc
AfaSci Inc
Affectis Pharmaceuticals AG
Akelos Inc
Algiax Pharmaceuticals GmbH
Algomedix Inc
Alion Pharmaceuticals Inc
Allergan Plc
Allodynic Therapeutics LLC
AlphaNavi Pharma Co Ltd
Amgen Inc
AnaBios Corp
Anavex Life Sciences Corp
Andros Pharmaceuticals Co Ltd
Angelini Group
AngioChem Inc
Anida Pharma Inc
AnyGen Co Ltd
AOBiome LLC
Aoxing Pharmaceutical Company Inc
APT Therapeutics Inc
Aptarion biotech AG
Aptinyx Inc
Aquilus Pharmaceuticals Inc
Araim Pharmaceuticals Inc
Arena Pharmaceuticals Inc
Artelo Biosciences Inc
Asahi Kasei Pharma Corp
Asarina Pharma AB
Astellas Pharma Inc
Astraea Therapeutics LLC
AstraZeneca Plc
Astrocyte Pharmaceuticals Inc
AusCann Group Holdings Ltd
Avanir Pharmaceuticals Inc
Avilex Pharma ApS
Axsome Therapeutics Inc
BCI Pharma SA
Bioasis Technologies Inc
Biodol Therapeutics SAS
BioElectron Technology Corp
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
BioHealthonomics Inc
Bioiberica SAU
Blackthorn Therapeutics Inc
Bol Pharma
Bsense Bio Therapeutics Ltd
Calchan Ltd
Cara Therapeutics Inc
Cavion LLC
CCH Pharmaceuticals ApS
CDA Research Group Inc
Celgene Corp
Cellatoz Therapeutics Inc
Centrexion Therapeutics Corp
Cerecin Inc
Cerecor Inc
CerSci Therapeutics Inc
Charleston Laboratories Inc
Chromocell Corp
Circuit Therapeutics Inc
Citragen Pharmaceuticals Inc
Cleveland Diabetes Care Inc
Clexio Biosciences Ltd
Coda Biotherapeutics Inc
Corium International Inc
Crossject SA
Cryno LLC
CrystalGenomics Inc
Curatis AG
CURx Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Daya Drug Discoveries Inc
DelNova Inc
Dompe Farmaceutici SpA
Eicosis LLC
Eli Lilly and Co
EnhanX Biopharm Inc
Epalex Corp
Exodos Life Sciences Limited Partnership
Expression Drug Designs LLC
Exxel Pharma Inc
Four Chuankeruide Pharmaceutical Co Ltd
GABA Therapeutics Inc
GB Sciences Inc
Glialogix Inc
Grace Therapeutics LLC
Grunenthal GmbH
GW Pharmaceuticals Plc
H. Lundbeck AS
Hana Pharm Co Ltd
Helixmith Co Ltd
Hoba Therapeutics ApS
ICE Therapeutics Ltd
Ichnos Sciences Inc
Imbrium Therapeutics LP
Immune Pharmaceuticals Inc
Impel NeuroPharma Inc
Initiator Pharma AS
InKemia IUCT Group SA
InMed Pharmaceuticals Inc
InStar Technologies AS
Intec Pharma Ltd
Integral Molecular Inc
IntelGenx Corp
Intellipharmaceutics International Inc
Invisio Ltd
Ionis Pharmaceuticals Inc
Ipsen SA
iQure Pharma Inc
Jeil Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Corp Ltd
Johnson & Johnson
JT Pharmaceuticals Inc
Kancera AB
KannaLife Sciences Inc
Kineta Inc
Klaria Pharma Holding AB
Knopp Biosciences LLC
Kolon Life Science Inc
Komipharm International Co Ltd
Krisani Bio Sciences Pvt Ltd
Lateral Pharma Pty Ltd
Lexicon Pharmaceuticals Inc
Living Cell Technologies Ltd
Lohocla Research Corp
Luye Pharma Group Ltd
MannKind Corp
Mapi Pharma Ltd
MD Biosciences GmbH
Medifron DBT Co Ltd
MEDRx Co Ltd
Medytox Inc
Merck & Co Inc
Merz Pharma GmbH & Co KgaA
MindImmune Therapeutics Inc
Mitsubishi Tanabe Pharma Corp
Mundipharma International Ltd
NAL Pharmaceuticals Ltd
Nanomerics Ltd
NeurAxon Pharma Inc
Neurim Pharmaceuticals Ltd
Neuro Vigor LLC
NeuroCycle Therapeutics GmbH
Neurodyn Life Sciences Inc
NeuroFix Therapeutics LLC
Neurona Therapeutics Inc
NeurOp Inc
NeuroPn Therapeutics LLC
NeuroTherpia Inc
Newron Pharmaceuticals SpA
Nippon Chemiphar Co Ltd
Nippon Zoki Pharmaceutical Co Ltd
NoNO Inc
Novaremed AG
Novassay SA
Noveome Biotherapeutics Inc
NutriBand Inc
OKYO Pharma Ltd
Old API Wind-down Ltd
OliPass Corporation
OliX Pharmaceuticals Inc
Orexigen Therapeutics Inc
OWP Pharmaceuticals Inc
Panag Pharma Inc
Panaxia Pharmaceutical Industries Ltd
Paracelsus Neuroscience I LLC
Patagonia Pharmaceuticals LLC
Pharmaleads SA
Pharmnovo AB
Phosphagenics Ltd
Pivot Pharmaceuticals Inc
PixarBio Corp
PlantForm Corp
Priavoid GmbH
PRISM Pharma Co Ltd
Promius Pharma LLC
ProNeurogen Inc
Qingdao Chia Tai Haier Pharmaceutical Co Ltd
RAFT Pharmaceuticals
RaQualia Pharma Inc
Re-Pharm Ltd
Regeneus Ltd
Relieve Genetics Inc
Revance Therapeutics Inc
Romark Laboratories LC
Rottapharm Biotech Srl
Saniona AB
Sarfez Pharmaceuticals Inc
Satsuma Pharmaceuticals Inc
Scientus Pharma Inc
Scilex Holding Co
Serentrix LLC
Seurat Therapeutics Inc
Shanghai Junshi Bioscience Co Ltd
Shanghai SIMR Biotech Co Ltd
Shenox Pharmaceuticals LLC
Shin Nippon Biomedical Laboratories Ltd
Shionogi & Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Signal Pharma Ltd
Sollis Therapeutics Inc
Sorrento Therapeutics Inc
Sosei Heptares
SpineThera Inc
Stem Cell Medicine Ltd
Suda Pharmaceuticals Ltd
Sumitomo Dainippon Pharma Co Ltd
Synerkine Pharma BV
Syntrix Biosystems Inc
Techfields Pharma Co Ltd
Terran Biosciences Inc
Teva Pharmaceutical Industries Ltd
Theranexus SAS
Titan Pharmaceuticals Inc
Topical Innovations BV
Toray Industries Inc
Trevena Inc
TrioxBio Inc
Vertex Pharmaceuticals Inc
Virobay Inc
VistaGen Therapeutics Inc
Vitality Biopharma Inc
Winston Pharmaceuticals Inc
Xalud Therapeutics Inc
Xoc Pharmaceuticals Inc
Yantai YenePharma Co Ltd
Yooyoung Pharm Co Ltd
Yuhan Corp
Zosano Pharma Corp
Number of Products under Development for Neuropathic Pain (Neuralgia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
1st Bio Therapeutics Inc
Abalone Bio Inc
Achelios Therapeutics Inc
Acorda Therapeutics Inc
Adynxx Inc
AfaSci Inc
Affectis Pharmaceuticals AG
Akelos Inc
Algiax Pharmaceuticals GmbH
Algomedix Inc
Alion Pharmaceuticals Inc
Allergan Plc
Allodynic Therapeutics LLC
AlphaNavi Pharma Co Ltd
Amgen Inc
AnaBios Corp
Anavex Life Sciences Corp
Andros Pharmaceuticals Co Ltd
Angelini Group
AngioChem Inc
Anida Pharma Inc
AnyGen Co Ltd
AOBiome LLC
Aoxing Pharmaceutical Company Inc
APT Therapeutics Inc
Aptarion biotech AG
Aptinyx Inc
Aquilus Pharmaceuticals Inc
Araim Pharmaceuticals Inc
Arena Pharmaceuticals Inc
Artelo Biosciences Inc
Asahi Kasei Pharma Corp
Asarina Pharma AB
Astellas Pharma Inc
Astraea Therapeutics LLC
AstraZeneca Plc
Astrocyte Pharmaceuticals Inc
AusCann Group Holdings Ltd
Avanir Pharmaceuticals Inc
Avilex Pharma ApS
Axsome Therapeutics Inc
BCI Pharma SA
Bioasis Technologies Inc
Biodol Therapeutics SAS
BioElectron Technology Corp
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
BioHealthonomics Inc
Bioiberica SAU
Blackthorn Therapeutics Inc
Bol Pharma
Bsense Bio Therapeutics Ltd
Calchan Ltd
Cara Therapeutics Inc
Cavion LLC
CCH Pharmaceuticals ApS
CDA Research Group Inc
Celgene Corp
Cellatoz Therapeutics Inc
Centrexion Therapeutics Corp
Cerecin Inc
Cerecor Inc
CerSci Therapeutics Inc
Charleston Laboratories Inc
Chromocell Corp
Circuit Therapeutics Inc
Citragen Pharmaceuticals Inc
Cleveland Diabetes Care Inc
Clexio Biosciences Ltd
Coda Biotherapeutics Inc
Corium International Inc
Crossject SA
Cryno LLC
CrystalGenomics Inc
Curatis AG
CURx Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Daya Drug Discoveries Inc
DelNova Inc
Dompe Farmaceutici SpA
Eicosis LLC
Eli Lilly and Co
EnhanX Biopharm Inc
Epalex Corp
Exodos Life Sciences Limited Partnership
Expression Drug Designs LLC
Exxel Pharma Inc
Four Chuankeruide Pharmaceutical Co Ltd
GABA Therapeutics Inc
GB Sciences Inc
Glialogix Inc
Grace Therapeutics LLC
Grunenthal GmbH
GW Pharmaceuticals Plc
H. Lundbeck AS
Hana Pharm Co Ltd
Helixmith Co Ltd
Hoba Therapeutics ApS
ICE Therapeutics Ltd
Ichnos Sciences Inc
Imbrium Therapeutics LP
Immune Pharmaceuticals Inc
Impel NeuroPharma Inc
Initiator Pharma AS
InKemia IUCT Group SA
InMed Pharmaceuticals Inc
InStar Technologies AS
Intec Pharma Ltd
Integral Molecular Inc
IntelGenx Corp
Intellipharmaceutics International Inc
Invisio Ltd
Ionis Pharmaceuticals Inc
Ipsen SA
iQure Pharma Inc
Jeil Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Corp Ltd
Johnson & Johnson
JT Pharmaceuticals Inc
Kancera AB
KannaLife Sciences Inc
Kineta Inc
Klaria Pharma Holding AB
Knopp Biosciences LLC
Kolon Life Science Inc
Komipharm International Co Ltd
Krisani Bio Sciences Pvt Ltd
Lateral Pharma Pty Ltd
Lexicon Pharmaceuticals Inc
Living Cell Technologies Ltd
Lohocla Research Corp
Luye Pharma Group Ltd
MannKind Corp
Mapi Pharma Ltd
MD Biosciences GmbH
Medifron DBT Co Ltd
MEDRx Co Ltd
Medytox Inc
Merck & Co Inc
Merz Pharma GmbH & Co KgaA
MindImmune Therapeutics Inc
Mitsubishi Tanabe Pharma Corp
Mundipharma International Ltd
NAL Pharmaceuticals Ltd
Nanomerics Ltd
NeurAxon Pharma Inc
Neurim Pharmaceuticals Ltd
Neuro Vigor LLC
NeuroCycle Therapeutics GmbH
Neurodyn Life Sciences Inc
NeuroFix Therapeutics LLC
Neurona Therapeutics Inc
NeurOp Inc
NeuroPn Therapeutics LLC
NeuroTherpia Inc
Newron Pharmaceuticals SpA
Nippon Chemiphar Co Ltd
Nippon Zoki Pharmaceutical Co Ltd
NoNO Inc
Novaremed AG
Novassay SA
Noveome Biotherapeutics Inc
NutriBand Inc
OKYO Pharma Ltd
Old API Wind-down Ltd
OliPass Corporation
OliX Pharmaceuticals Inc
Orexigen Therapeutics Inc
OWP Pharmaceuticals Inc
Panag Pharma Inc
Panaxia Pharmaceutical Industries Ltd
Paracelsus Neuroscience I LLC
Patagonia Pharmaceuticals LLC
Pharmaleads SA
Pharmnovo AB
Phosphagenics Ltd
Pivot Pharmaceuticals Inc
PixarBio Corp
PlantForm Corp
Priavoid GmbH
PRISM Pharma Co Ltd
Promius Pharma LLC
ProNeurogen Inc
Qingdao Chia Tai Haier Pharmaceutical Co Ltd
RAFT Pharmaceuticals
RaQualia Pharma Inc
Re-Pharm Ltd
Regeneus Ltd
Relieve Genetics Inc
Revance Therapeutics Inc
Romark Laboratories LC
Rottapharm Biotech Srl
Saniona AB
Sarfez Pharmaceuticals Inc
Satsuma Pharmaceuticals Inc
Scientus Pharma Inc
Scilex Holding Co
Serentrix LLC
Seurat Therapeutics Inc
Shanghai Junshi Bioscience Co Ltd
Shanghai SIMR Biotech Co Ltd
Shenox Pharmaceuticals LLC
Shin Nippon Biomedical Laboratories Ltd
Shionogi & Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Signal Pharma Ltd
Sollis Therapeutics Inc
Sorrento Therapeutics Inc
Sosei Heptares
SpineThera Inc
Stem Cell Medicine Ltd
Suda Pharmaceuticals Ltd
Sumitomo Dainippon Pharma Co Ltd
Synerkine Pharma BV
Syntrix Biosystems Inc
Techfields Pharma Co Ltd
Terran Biosciences Inc
Teva Pharmaceutical Industries Ltd
Theranexus SAS
Titan Pharmaceuticals Inc
Topical Innovations BV
Toray Industries Inc
Trevena Inc
TrioxBio Inc
Vertex Pharmaceuticals Inc
Virobay Inc
VistaGen Therapeutics Inc
Vitality Biopharma Inc
Winston Pharmaceuticals Inc
Xalud Therapeutics Inc
Xoc Pharmaceuticals Inc
Yantai YenePharma Co Ltd
Yooyoung Pharm Co Ltd
Yuhan Corp
Zosano Pharma Corp
